Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Nelarabine in newly diagnosed paediatric T-cell malignancies

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 644

Dr Kimberly Dunsmore - University of Virginia School of Medicine, Virginia, USA

Dr Dunsmore speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of nelarabine in new cases of paediatric T cell malignancies.

She describes the structure of the COG AALL0434 trial, with almost 2,000 patients randomised to receive escalating dose methotrexate without leucovorin rescue pegaspargase (CMTX) or High Dose MTX (HDMTX) leucovorin rescue, and intermediate and high-risk patients with T-ALL and T-LL were randomised to receive six 5-day courses of nelarabine.

Nelarabine was found to improve DFS for children and young adults with T-ALL, leading Dr Dunsmore to encourage its use as a new standard of care for this population


ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation